184 related articles for article (PubMed ID: 25354875)
1. FOXP3+ regulatory T-cell counts correlate with histological response in Crohn's colitis treated with infliximab.
Sloan S; Maxwell P; Salto-Tellez M; Loughrey MB
Pathol Int; 2014 Dec; 64(12):624-7. PubMed ID: 25354875
[TBL] [Abstract][Full Text] [Related]
2. Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease.
Ricciardelli I; Lindley KJ; Londei M; Quaratino S
Immunology; 2008 Oct; 125(2):178-83. PubMed ID: 18422560
[TBL] [Abstract][Full Text] [Related]
3. Therapy with anti-TNFα antibody enhances number and function of Foxp3(+) regulatory T cells in inflammatory bowel diseases.
Boschetti G; Nancey S; Sardi F; Roblin X; Flourié B; Kaiserlian D
Inflamm Bowel Dis; 2011 Jan; 17(1):160-70. PubMed ID: 20848510
[TBL] [Abstract][Full Text] [Related]
4. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease.
Van den Brande JM; Koehler TC; Zelinkova Z; Bennink RJ; te Velde AA; ten Cate FJ; van Deventer SJ; Peppelenbosch MP; Hommes DW
Gut; 2007 Apr; 56(4):509-17. PubMed ID: 17082252
[TBL] [Abstract][Full Text] [Related]
5. Pre-clinical Crohn's disease: diagnosis, treatment and six year follow-up.
Sorrentino D; Avellini C; Geraci M; Vadalà S
J Crohns Colitis; 2014 Jul; 8(7):702-7. PubMed ID: 24411923
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.
Baert FJ; D'Haens GR; Peeters M; Hiele MI; Schaible TF; Shealy D; Geboes K; Rutgeerts PJ
Gastroenterology; 1999 Jan; 116(1):22-8. PubMed ID: 9869598
[TBL] [Abstract][Full Text] [Related]
7. Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFα therapy.
Leal RF; Planell N; Kajekar R; Lozano JJ; Ordás I; Dotti I; Esteller M; Masamunt MC; Parmar H; Ricart E; Panés J; Salas A
Gut; 2015 Feb; 64(2):233-42. PubMed ID: 24700437
[TBL] [Abstract][Full Text] [Related]
8. Heightened Expression of CD39 by Regulatory T Lymphocytes Is Associated with Therapeutic Remission in Inflammatory Bowel Disease.
Gibson DJ; Elliott L; McDermott E; Tosetto M; Keegan D; Byrne K; Martin ST; Rispens T; Cullen G; Mulcahy HE; Cheifetz AS; Moss AC; Robson SC; Doherty GA; Ryan EJ
Inflamm Bowel Dis; 2015 Dec; 21(12):2806-14. PubMed ID: 26332314
[TBL] [Abstract][Full Text] [Related]
9. Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab.
Li Z; Arijs I; De Hertogh G; Vermeire S; Noman M; Bullens D; Coorevits L; Sagaert X; Schuit F; Rutgeerts P; Ceuppens JL; Van Assche G
Inflamm Bowel Dis; 2010 Aug; 16(8):1299-310. PubMed ID: 20196149
[TBL] [Abstract][Full Text] [Related]
10. Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn's disease.
Juanola O; Moratalla A; Gutiérrez A; Sempere L; Zapater P; Giménez P; Almenta I; Peiró G; González-Navajas JM; Such JF; Francés R
J Gastroenterol; 2015 Jul; 50(7):758-68. PubMed ID: 25500977
[TBL] [Abstract][Full Text] [Related]
11. The influence of infliximab and adalimumab on the expression of apoptosis-related proteins in lamina propria mononuclear cells and enterocytes in Crohn's disease - an immunohistochemical study.
Eder P; Lykowska-Szuber L; Krela-Kazmierczak I; Stawczyk-Eder K; Zabel M; Linke K
J Crohns Colitis; 2013 Oct; 7(9):706-16. PubMed ID: 23021876
[TBL] [Abstract][Full Text] [Related]
12. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease.
Geboes K; Rutgeerts P; Opdenakker G; Olson A; Patel K; Wagner CL; Marano CW
Curr Med Res Opin; 2005 Nov; 21(11):1741-54. PubMed ID: 16307694
[TBL] [Abstract][Full Text] [Related]
13. T2 enhances in situ level of Foxp3+ regulatory cells and modulates inflammatory cytokines in Crohn's disease.
Li G; Ren J; Wang G; Gu G; Hu D; Ren H; Hong Z; Wu X; Liu S; Li J
Int Immunopharmacol; 2014 Feb; 18(2):244-8. PubMed ID: 24369313
[TBL] [Abstract][Full Text] [Related]
14. Discrete changes in circulating regulatory T cells during infliximab treatment of Crohn's disease.
Hvas CL; Kelsen J; Agnholt J; Dige A; Christensen LA; Dahlerup JF
Autoimmunity; 2010 Jun; 43(4):325-33. PubMed ID: 20298123
[TBL] [Abstract][Full Text] [Related]
15. Infliximab inhibits activation and effector functions of peripheral blood T cells in vitro from patients with clinically active ulcerative colitis.
Dahlén R; Strid H; Lundgren A; Isaksson S; Raghavan S; Magnusson MK; Simrén M; Sjövall H; Öhman L
Scand J Immunol; 2013 Sep; 78(3):275-84. PubMed ID: 23713660
[TBL] [Abstract][Full Text] [Related]
16. Increase of regulatory T cells in ileal mucosa of untreated pediatric Crohn's disease patients.
Reikvam DH; Perminow G; Lyckander LG; Gran JM; Brandtzaeg P; Vatn M; Carlsen HS
Scand J Gastroenterol; 2011 May; 46(5):550-60. PubMed ID: 21281255
[TBL] [Abstract][Full Text] [Related]
17. Use of a 99mTc labeled anti-TNFalpha monoclonal antibody in Crohn's disease: in vitro and in vivo studies.
D'Alessandria C; Malviya G; Viscido A; Aratari A; Maccioni F; Amato A; Scopinaro F; Caprilli R; Signore A
Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):334-42. PubMed ID: 17464276
[TBL] [Abstract][Full Text] [Related]
18. Histological inflammation in Crohn's disease in deep remission during treatment with anti-TNFα.
Tursi A; Elisei W; Picchio M; Brandimarte G
Dig Liver Dis; 2014 Jun; 46(6):575-6. PubMed ID: 24602485
[No Abstract] [Full Text] [Related]
19. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
Gao Q; Hogezand RA; Lamers CB; Verspaget HW
Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
[TBL] [Abstract][Full Text] [Related]
20. Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease.
Agnholt J; Dahlerup JF; Buntzen S; Tøttrup A; Nielsen SL; Lundorf E
Aliment Pharmacol Ther; 2003 Mar; 17(5):703-10. PubMed ID: 12641520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
